{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapeutic+immune+globulin", "query": { "intervention": "therapeutic immune globulin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6722, "total_pages": 673, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapeutic+immune+globulin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T12:16:43.536Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03316274", "title": "Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Kaposi Sarcoma", "HIV/AIDS", "Immunosuppression" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-05-07", "completion_date": "2021-06-30", "has_results": false, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03316274" }, { "nct_id": "NCT05113251", "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "HER2-positive Early Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 927, "start_date": "2021-10-25", "completion_date": "2027-04-30", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 22, "location_summary": "Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05113251" }, { "nct_id": "NCT02311920", "title": "Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliosarcoma", "Supratentorial Glioblastoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-04-16", "completion_date": "2022-12-22", "has_results": false, "last_update_posted_date": "2023-01-10", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 11, "location_summary": "San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311920" }, { "nct_id": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "Solid Tumor", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Melanoma", "Bladder Cancer" ], "interventions": [ { "name": "MRx0518", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "4D pharma plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2019-01-10", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 5, "location_summary": "Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637803" }, { "nct_id": "NCT01608594", "title": "Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "administration of ipilimumab10mg/kg", "type": "DRUG" }, { "name": "administration of ipilimumab 3mg/kg + HDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-05-21", "completion_date": "2017-02-27", "has_results": false, "last_update_posted_date": "2018-08-28", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01608594" }, { "nct_id": "NCT00220766", "title": "Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunologic Deficiency Syndrome", "Agammaglobulinemia", "Severe Combined Immunodeficiency", "Wiskott-Aldrich Syndrome", "Common Variable Immunodeficiency" ], "interventions": [ { "name": "Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Dextrose, 5% in Water", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2002-08", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2009-09-25", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "North Palm Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220766" }, { "nct_id": "NCT01105702", "title": "Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-05", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 2, "location_summary": "Summit, New Jersey • New York, New York", "locations": [ { "city": "Summit", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105702" }, { "nct_id": "NCT01344824", "title": "Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2010-03", "completion_date": "2016-07-20", "has_results": true, "last_update_posted_date": "2017-10-30", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 4, "location_summary": "Asheville, North Carolina • Chapel Hill, North Carolina • New Bern, North Carolina + 1 more", "locations": [ { "city": "Asheville", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "New Bern", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01344824" }, { "nct_id": "NCT00270894", "title": "Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm" ], "interventions": [ { "name": "epirubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2005-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2012-03-20", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 7, "location_summary": "Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Billings", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00270894" }, { "nct_id": "NCT00673218", "title": "The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Allergy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Xolair", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Creighton University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "19 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2007-06", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2012-07-06", "last_synced_at": "2026-09-29T12:16:43.536Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673218" } ] }